NCT06843447 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06843447
Title	A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Acronym	MK-5909-003
Recruitment	Recruiting
Gender	female
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	fallopian tube cancer peritoneum cancer ovarian serous carcinoma
Therapies	Pembrolizumab + Raludotatug deruxtecan Carboplatin + Raludotatug deruxtecan Paclitaxel + Raludotatug deruxtecan Bevacizumab + Raludotatug deruxtecan
Age Groups:	adult \| senior
Covered Countries	USA \| ISR \| GBR \| ESP

NCT06843447
Clinical Trial Detail